LB Pharmaceuticals raises $150M in private placement for pipeline expansion

LB PHARMACEUTICALS INC

Gross proceeds of ~$150M from sale of 3,577,560 shares at $34.94 and pre-funded warrants for 715,513 shares.
Proceeds to fund LB-102 expansion into negative symptoms of schizophrenia and Alzheimer's agitation/psychosis.
Investors include Adage Capital, BB Biotech, Caligan, Commodore, Deep Track, Farallon, Janus Henderson, and others.
Placement agents: Leerink Partners and Piper Sandler; expected close July 30, 2026.
Registration rights agreement to file resale registration statement within 90 days of closing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.